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INTRODUCTION
.Prior to 1959 chloramphenicol had been considered
relatively free from side effects other than those of bone
marrow depression (1) and bacterial or fungal superinfection.
(2)

The concern regarding the increasing incidence of

nursery infections had resulted in widespread use of antibiotics for prophylaxis as well as therapy.(3t4)

Chloram-

phenicol gained popularity in this field because of its
greater effectiveness against those bacterial agents which
more commonly cause trouble in the premature nursery, i.e.
staphylococci and gram negative rods as well as streptococci and pneumococci.

However, prior to the Parke, Davis

and Company announcement of neonatal chloramphenicol intoxication in 1959,(5) the recommended dose was 100 to 150mg
per kilogram of body weight per day for children of 15 kilograms or less.(6-9)
It is the purpose of this paper to present not only
the findings of the various investigators who made the initial observations, but also the work of those who presented
a physiologic explanation of the drug's toxicity when given
to newborn and premature infants in excessive doses.

1

STATEMENT OF THE PROBLEM
In 1959 workers in a number of newborn nurseries observed an increase in toxic reactions and death rates, especially among premature infants, following the administration
of this antibiotic.(10-14)

These infants died in acute cir-

culatory collapse.
In some instances sepsis was blamed for these deaths;
however, no specific evidence of infection was found.

Van

Gelder (15) questioned sepsis as the cause of death because
of the frequency of myocardial failure in these infants.
Previous reports had not listed myocardial disease as a common feature of neonatal sepsis.

Alltibiotic dosages were in-

creased and additional deaths resulted until the common etiology was recognize~.

Thereafter dosages were reduced and

no more unexplained deaths occurred.

Post mortem findings

attributable to the use of chloramphenicol were absent in
all organ systems including the hemat,opoietic system.
Symptoms first appeared two to five days after continued therapy with chloramphenicol doses of 100 mg per kilogram
per day or more.

In many cases the symptoms appeared in the

order of abdominal distention, with or without emesis, progressive pallid cyanosis, vasomotor collapse, frequently accompaft
nied by irregular respiration, and sometimes death within a few

2

hours after the onset of these symptoms.
ferred to

~n

some

as the "gray syndrome".

~nst~tut~ons

progress~on
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with
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h~gher
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chloramphen~col
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was not used extensively in newborn infants prior to 1957 and
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of
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(16,17).
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picture,
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e. acute circulatory col-

lapse, had been previously noted by European observers (19-21)
~n

adults and children following three to five days of high

doses of chloramphenicol, but
has been
Vit~ ~n

assoc~ated

w~th

few exceptions (9)

with therapy of sa1monella

1956 reported vasomotor collapse

dur~ng

tration of chloramphenicol in the absence of
fect~on.

th~s

infect~ons.

the adminis-

bact~rial
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He suggested that chloramphenicol had an adverse

effect on carbohydrate
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hav~ng

found

fast~ng

hypo-

glycemia in normal adults after five to ten days of oral therapy and a return to normal ten days after the drug was
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d~scon-

tinued.

He was unable to determine the exact cause of this

hypoglycemia but believed it involved a toxic action in the
liver.

The acute cardiovascular collapse was believed to

be directly related to this hypoglycemic action.

Groh (22)

found delayed glucose breakdown in infants during chloramphenicol therapy.

This delay was reversed when B vitamins

were administered during treatment.

He ascribed this delay

to a decrease in B vitamin coenzymes in the G. I. tract.
Patterson (23) observed anaphylactoid shock and vasomotor
collapse during the administration of chloramphenicol.

The

patient developed pruritis thirty minutes following ingestion
of the .first dose and in a few minutes developed angioneurotic edema with laryngeal involvement.

Blood pressure was

unobtainable but treatment with epinephrine, theophylline,
and diphenhydramine resulted in recovery in a few days.

This

reaction was also reported by Chatterjee (20) and Stephens
(24) in 1950 and by Welch (25) in 1957 who observed typhoid
fever deaths after initial improvement with chloramphenicol.
This was considered to be a Jarisch-Herxheimer reaction from
endotoxins released from destroyed virulent bacilli which
overwhelmed the already weakened patient.

Deaths in children

under the age of three resulting from bacterial superinfection
following chloramphenicol therapy have been mentio.ned (2).
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These followed vomiting and diarrhea as a result of the superinfection by resistent staphylococci.
Substitution of the acid in the ester could produce
an increased toxicity if the absorption rate was increased,
(26) but this alone has had no qualitative effect on toxicity since similar deaths have been reported with the palmitic acid and sodium succinate esters and the microcrystalline suspension.
Studies were performed to determine if there exists
any difference in the metabolic products of chloramphenicol

in the serum and urine of newborn infants from those in the
adult.

Dill (27) found the nitro compounds to be identi-

cal to those in the adul,\,," He also discovered a new metabolite of chloramphenicol, a glycolic acid analogue, which
possesses a low order of toxicity and

is'unl~ely

to have

produced the side reactions seen in infants.
Sutherland (10) considered methemoglobinemia because
of the gray pallor.

Although no determinations for methemo-

globin were done this possibility was discounted because of
the absence of the characteristic slate cyanosis and chocolate colored blood and tissue during life or at necropsy.
Mongelli and Carrozzini (28) suggested that chloramphenicol
has a primary toxic effect on the autonomic nervous system.
The mechanism of action is unknown but there is con-

5

$iderable evidenoe in the literature whioh suggests that the
toxio manifestations of ohlorampheniool in infants are related to poor liver and kidney funotion.

This reduced de-

toxication and exoretion leading to retention of the free drug
results in toxio levels of 100 miorograms per milliliter
after three days of oontinued therapy with high doses.
REPORT OF CASES

Two abstraoted cases will be presented to illustrate
both the typical onset of symptoms and the insidious way in
which this toxic effect manifests itself.
CASE 1.(10) The patient was a 3,320 gm infant
born of a Negro, married, Group A, Rh-positive,
primipara with negative serologic test for syphilis at 44 weeks' gestation. The mother had had
no prenatal care and was admitted in labor with
albuminuria and a systolic blood pressure over
200 mm. Hg.
After a five-and-one-half hour labor with
no medication the infant was delivered by vertex presentation under nitrous-oxide and oxygen
anesthesia with a mediolateral episiotomy. At
birth the infant had an Apgar score of 6 and
was noted to be meconium stained.
A foul odor was encountered on physical
examination. The time of rupture of the maternal membranes was unknown, and 50,000 units
of procaine penicillin and 250 mg of chloramphenicol were started intramuscularly every
eight hours. Menadione sodium bisulfite 5 mg
was given. At 8 hours the infant nursed at the
breast. At 2 days rectal temperature was 99 F.
The infant did not seem ill and he was circumcised.
At 4 days of age the infant developed a
gray oolor and a cold moist skin in spite of
a temperature of 99 F. The infant died at 106
hours of age, 8 hours after the onset of vascu-
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lar collapse. He received 250 mg of chloramphenicol 9 times in 72 hours, or 230 mg per
kilogram per 24 hours.
At postmortem examination the lungs
~eighed 40 gmt and there was lobular consolidation. The heart weighed 21 gm and was
moderately dilated. On microscopic examination there was patchy atelectasis and emphysema without an apparent causative factor.
There was a trivial pneumonitis. Quite extensive focal myocardial degeneration with
pyknosis was seen. There was some vacuolization of proximal renal tubules. No bone-marrow changes were noted.
CASE II.(13) This 1,490 gram, Negro, female
infant was born following a pregnancy which
was complicated by vaginal bleeding during
the third trimester. This was the fifth pregnancy for this 25-year-old mother with type
no", Rh-positive blood, who had been in good
health. A normal spontaneous delivery produced
a small weak infant with poor respirations and
a weak Moro response. There was no period of
apnea.
The infant was placed in an incubator
in an atmosphere of high humidity and 35% oxygen. The infant's vigor and strength improved
and the oxygen was discontinued at the end of
24 hOUTS. Color, cry and respirations were
label.l&d tfgood tt by the attending nurses on
repeated occasions, and there was no record
of difficulty during the second day of life.
At 24 hours of age, 5% glucose in water
was given orally by means of a bottle and nipple. This was repeated at 3-hour intervals on
four occasions. A formula of milk was given
at 36 hours of age and repeated every 3 hours.
The first dose of chloramphenicol (93 mg)
was given at 48 hours of age. At 62 hours of
age, the infant's color was recorded as being
ffd-q.skyU 'and oxygen was administered for 5 minutes.
This type of episode occurred at 14 and
16 hours, respectively, after the first and
second doses of chloramphenicol. There followed
a 12-hour period without difficulty, during
which time the third and fourth doses of chlor7

amphenicol were given. At 74 hours of age,
the infant became cyanotic and the house
physician was called. Oxygen was prescribed,
with proper restrictions, and the chloramphenicol was continued. The infant ate well
at the next feeding, but she became "very
cyanotic" and her respirations were very irregular and shallow. The milk formula was
replaced with glucose in water which she took
without difficulty for two feedings.
At 84 hours of age (36 hours after the
first dose of medication), she had a momentary
period of apnea. However, she took the next
four routine feedings without trouble, and her
color and respirations were good; there were
no reports of difficulty during this period.
At 100 hours of age (52 hours after the first
dose of chloramphenicol), respirations suddenly
ceased and she could not be revived. Sf§) had
received 560 mg Chloromycetin Palmitate
divided in six doses during a period of 52 hours.
The post-mortem examination showed ~a
ture pulmonary structures. There were scattered
areas of focal atelectasis. There was no lesion
demonstrable which seemed to be of sufficient
magnitude to be the cause of death.
CLINICAL STUDY
As a result of the increased mortality rates in 1958
and 1959, following both prophylactic administration and
treatment with chloramphenicol, several series of these unexplained deaths were collected.

Burns et ale (7) studied four

groups of premature infants treated after premature rupture
of membranes.
Group I received no antibiotic, group II received chloramphenicol alone 100-165 mg per kilogram per day; group III
received perdcillin 1.50,OOO-600,oOOu per day and streptomycin
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,
50 mg per

k~logram

per day.

Group IV

all

rece~ved

ant~bi-

ot~cs.

The mortality rates of the groups

chlorampheni-

g~ven

col were markedly elevated from the other two groups.
terestingly, the mortality of the non-treated group
~dentical

to the

treated with
course

A
and

chloramphen~col

s~milar

of 1958

in these deaths.
ten

~nfants

per

k~logram

infection.

followed a

wa~

The infants

typ~cal cl~nioal

to that presented earlier.

retrospect~ve

Apr~l

group.

pen~cill~n-streptomyc~n

In-

study by Lischner (22) et ale in March

~cluded

There were common factors in

who died.
was

a search for the common

g~ven

n~ne

et~ology

of the

Chloramphenicol in doses of over 113 mg
early for prevention or treatment of

After two to five days of treatment initial im-

provement of symptoms was followed by vascular collapse and
sudden death.

Extensive

ried out by both
stud~es

m~crobiological

bacteriolog~c

studies had been car-

cultures and

on HeLa cells, monkey kidney and

v~rus

l~ve

isolation

animals.

One

of their 42 infants in this series had a single colony of
Staphylococcus aureus and all the viral
Post mortem

exam~nation fa~led

stud~es

were negative.

to reveal a cause of death.

Van Gelder (15) et ale reported on two outbreaks of
neonatal deaths but the
not become

ev~dent unt~l

associat~on w~th

the

9

toxic~ty

chloramphenicol did

was announced by Parke,

Davis & Company.
of age.

One of these deaths was in an infant 25 days

The maximum danger period for chloramphenicol toxic-

ityhas not been established t but Lischner indicates that
infants three weeks and older can tolerate 200 mg per kilogram per day provided they are not severely ill or dehydrated
and further weakened by chloramphenicol therapy.

The current

recommended dosage by Parke t Davis, & Co. for premature and
newborn infants is 25 mg per kilogram per day.

Full term in-

fants may receive 25-50 mg per kilogram per day.(29)
Only one case of the ttgray syndrome" has been reported
in older infants.

Morton (30) describe,s abdominal distention,

progressive cyanosis, vasomotor collapse with irregular respiration and finally apnea in a six week old infant following
a dosage of 750 mg intramuscularly in the first twelve hours,
or 166 mg per kilogram.

She asc,ribes the reason for toxicity

at this age to anuria.
Chloramphenicol toxicity has been extensively studied
in animals.' The report of Kent (31) et ale illustrates the
desirability of obtaining toxicity data on newborns as well
as in the adult by their study on 394 newborn mice and two
groups of adult mic,e.

Their test animals received 230-2400

mg per kilogram of chloramphenicol for five successive days
and the contrql animals received 0.1 molar sodium succinate
in 5% glucose.
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The LD50 for newborn mioe in this experiment was
315

!

22.6 mg per kilogram per 24 hours and the LD50 for adult

mioe was 1,675 Z 35.6 mg per kilogram per 24 hours.

This is

5.3 times the LD50 of newborns.
Similar studies by Smith et ale showed the LD50 for
adult mioe to be 245 mg per kilogram of body weight.

They

also were able to produoe a drop in bJ.ood pressure following
intravenous doses of ohlorampheniool.

With

~igh

doses, fol-

lowing the fall in blood pressure, respiratory failure and
death resulted.(32)
BLOOD LEVEL STUDIES
Following publioation of numerous reports in 1959, the
Researoh Division of Parke, Davis and Company published a
summary of the blood levels of different forms of ohloramphenicol in infants.(33)

A oolorimetrio prooedure was used to determine the total
nitro oompounds and aryl amines in the samples.

This prooedure

was desoribed by Glazko (34) in 1949 and is not speoifio for
aotive ohloramphenicol sinoe the inactive degradation produots
are inoluded in the determination.

The method devised is

based on reduction of the aromatic 'nitro group to a primary
amine with titanous chloride or metallic zinc, followed by
diazotization and coupling of the resulting amines.
sults are expressed in chloramphenicol equivalents.
11

All re-

Determinations of the free and unconjugated portion of
chloramphenicol provide data on the effective levels of chloramphenicol and are performed by means of a turbidimetric procedure against Shigella sonnei.(32)

This method is, however,

less valuable than the colorimetric procedure for absorption
and excretion studies.
Chloramphenicol palmitate is a water insoluble ester
which is absorbed slowly and poorly following hydrolysis in
the intestine.

An initial dose of 100 mg per kilogram and

25 mg per kilogram per 6 hours is necessary to maintain a
minimal therapeutic blood level of 10 micrograms per milliliter. (17)

Following the control of particle,size"aatis-

factory blood levels oould be maintained with the reoommended
doses.
The series included infants under forty-eight hours of
age and children ranging from one to twelve years of age.
single dose of 50 mg per kilogram was administered.

A

The older

age group obtained maximum blood levels in two hours and by
four hours half of the maximum level remained.

In the new-

born ,the maximum was reached in twelve hours indicating reduoed hydrolysis and absorption.

The half-life was prolonged

to twenty-eight hours.
The microcrystalline form of chloramphenicol was designed for intramuscular use.
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The slow rate of absorption

and rapid excretion produces low but prolonged blood levels.
A single dose of 50 mg per kilogram was administered to 9
infants under forty-eight hours of age.

The maximum blood

level with this form was reached in twenty-three hours.

This

was followed by a slow rate of fall and later by an acceleration of the rate of removal which was believed due to either
less absorption in the later periods or interval maturation
of the infants hepatic and renal systems.
This series showed that in most cases the infants one
to four days of age had significantly higher blood levels
than the infants that were fourteen to twenty-three days of
age.
Chloramphenicol sodium succinate is the preferred and
only suitable parenteral form for intramuscular, intravenous,
or subcutaneous use.
\

Hydrolysis occurs in the tissues with

liberation of free chloramphenicol.

The study included

children four to five years of age, infants ten to sixteen
days of age and newborn infants one to two days of age.

The

dosage was 50 mg per kilogram except for the ten to sixteen
day age group which received 25 mg per kilogram.
High levels were obtained within a few hours in all
groups indicating rapid absorption; however the half-life was
twenty-six hours in the newborn group compared to ten hours
in the second group and four hours for the older children.
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The prolonged half-life in the newborn group indicates that
elimination of the nitro compounds is slow.
Chloramphenicol blood levels in newborns were studied by
Wiltse (35) at the University of Nebraska Hospital.

A total

of 32 i:nfants was incorporated into this study and divided
into groups according to weight.

Infants weighing 2500 grams

or less received 25 mg per kilogram per 24 hours and those
weighing over 2500 grams received 50 mg per kilogram per 24
hours.

All infants received an initial loading dose of 50 mg

per kilogram.

Chloramphenicol succinate was given intramuscu-

larly in divided doses every 12 hours.
Chemical assay of heparinized plasma samples was done
by the colorimetric procedure of Glazko (34) et ale

The re-

sulting blood levels were expressed in micrograms per milliliter o:f chloramphenicol equivalents which included total
nitro compounds.
One group included 19 infants and was divided into 4
subgroups according to weights of the infants.

All these in-

fants received only a single dose of 50 mg per kilogram"per
7

milliliter,.

Table I compares the half-lives of four weight

ranges, i.e. 1000-2500 grams, 2500-3000 grams, 3000-3500 grams,
and weights over 3500 grams.
from the 6-18 hour

"K"

order kinetics apply_

The half-lives were calculated

value, on the assumption that firstA graph of the mean values of all
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patients in table I is shown in figure 1.

There appears to

be a significant increase in the half-life with increasing
weight of the infant as shown in figure 1.

This may be due

to increased amounts of adipose tissue in larger babies.
Glazko (}6) found that chloramphenicol was widely distributed
in all body tissues but did not i.nclude adipose tissue in his
analysis.
Table II represents another group of newborns divided
into 2 subgroups according to weight.

Plasma levels were ob-

tained on samples drawn 6 hours after the first dose on days
1, 3, and 5, i.e. at 6, 54, and 102 hours.
The mean values for the larger infant group are approximately twice those of the smaller group indicating that full
term babies probably do not eliminate the antibiotic any more
satisfactorily than the prematures.
cre~sing

This suggests that in-

the dose in infants weighing 2500 grams or more is

not justified and can even be dangerouse

Sutherland (37) re-

cently recommended doses of 25 mg per kilogram per 24 hours
for premature and full term infants under one week of age and
50 mg per kilogram per 24 hours for all infants over one week
of age.

Day 3 is the most significant with two blood levels

within the toxic range.

Both of these infants were large

babies well over 2500 grams.

Lowering the dose schedules

below 25 mg per kilogram per 24 hours would result in inef-
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fectiveblood levels of 10 micrograms per milliliter or less
in some cases.

In this series one sample was below 10 micro-

grams a't the 25 mg per kilogram per 24 hours dosage.
The wide standard deviation indicates that toxic levels
can be reached with these doses in some cases, thus use of
this antibiotic in newborn infants requires closely monitored
blood levels to assure safe administration.
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TABLE I.
Patient
number

Chloramph.enicol Half-lives in Newborn Infants
Birth Weight
(kg)

6-18 hr. "k"

Half-life
(hrs.)

1
2
3
4

1.984
1.210
1.990
2.168
1.838

15.4
21.1
21.9
22.9

10.7
14.6
15.2
1:2&2
Mean 14.1
SDj;,2.6

5
6
7

2.533
2.573
2.520
2.542

27.6
21.4
21.8

19.1
14.8
1ge1
Mean 1.3
SDj;,204

8
9
10
11
12
13
14

3.020
3.160
30225
3.422
3.290
3.232
3.223
3.225

33.7
23.5
24.8
26.1
41.9
26.2
16 .. 1

23.4
16.3
17 .. 2
18.1
29.0
18 02
11.2
Mean 19.1
SDV·7

15
16
17
18
19

3.500
3.512
3.561
3.885
4.104
3.712

25.5
22.4
43.3
37.0
26.0

17.7
15.5
30.0
25.6
18.0
Mean 21.4
SDj;,7.2
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TABLE II. Chloramphenicol Plasma Levels (micrograms per milliliter) in Newborn Infants following Doses of 25mg/kg/24hrs. in
Group I. and 50mg/kg/24hrs. in Group II.
- Weight
(kg)
Group I
1.707
2.205
2.290
2.245

Group II
2.760
2.915
3.130
3.133
3.225
3.339
3.390
3.740
4.907

Dosage
mg/kg/24hrs.
23.4
22.7
21.8
26.7

50.7
51.5
47.9
51.1
49.6
50.9
50.1
48.1
48.9

Day 1
(6 hra.)

Day 3
(54 hrs.)

Day 5
(102 hrs.)

29.5
29.0
17.1
12. 0
Mean 23.8

37.7
24.5
34.2
22 ·Z
Mean 32.3

16.7
4.7
51.3
l
Mean 2.4

SD.±,6.3

SD.±,5.8

SD.±,20.2

20.2
28 • 1
Mean 51.9

57.8
26.3
66.8
128.9
58.1
99.3
46.3
25.3
21 •1
Mean 62.2

59 .. 0
25.4
43.1
64.6
36.5
46.6
40.8
20.2
24 • 0
Mean 43.4

SD.±,19. 6

SD.±,33.3

SD.±,14.7

28.1
76.8
72.5
50.7
57.1
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METABOLIC DISPOSITION OF CHLORAMPHENICOL
It is apparent that several functions are quantitatively
less well developed in the infant as compared to the adult.
These include reduced glomerular filtration and tubular secretion as well as a number of enzymatic reactions.

Glazko

et ale (38) reported that chloramphenicol was inactivated
through conjugation with glucuronic acid.

Brown and Zuelzer

(39,40) later showed that the fetal liver at mid-gestation
posseses no glucuronide conjugating activity.

The newborn

liver has about one-half the activity of the adult. but by
15-20 days of life the enzyme systems are comparable to the
adult.

They speculated that this inability to form glucuron-

ide may have resulted in the formation of an alternate and
more toxic metabolic product.
The deficiency in the newborn liver involved two enzymatic steps of the glucuronide conjugation pathway. (41)
Uridine diphosphate glucuronic dehydrogenase and glururonyl
transferase were deficient resulting
diphosphoglucuronic acid (UDPGA).

~n

absence of the uri dine

The UDPGA, combining with

the agent to be detoxified (bilirubin in these experiments),
results,~n

the bilirubin glucuronide, or the direct reacting

bilirubin.
Billing (42) demonstrated that the capacity to conjugate
bilirubin with glucuronic acid is not entirely confined to the
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liver and suggested that the formation of the monoglucuronide
may be' effected in the kidney.

In vitro studies showed that

the kidney has as high as one-fourth the conjugating activity
of the liver.
The amount of a dose of chloramphenicol recovered in
twenty-four-hour urine approaches 90% in the adult human.
Only 5-15% of this is microbiologically active or free chloramphenicol and about 90% is excreted as inactive nitro compounds, mainly the glucuronide.

The remainder of the dose

excreted includes a small amount of products of hydrolysis,
less than 3% excreted as aryl amines into the bile, and less
than 1% excreted into the feces
rivatives.(43)

a~

aryl nitro and amine de-

These mechanisms of degredation of the chlor-

amphenicol molecule occur at the sites illustrated:

,hydrolysis

HI

reduction' to
aryl amines

I

~ NfCO-CHC12
,

°2 N

C-C-CH OH
2
\ glucuronide
linkage

H H

To determine the potential toxicity of chloramphenicol
and its metabolic products, the glucuronide was given in large
amounts to rats without side effects.(44)

Indirect studies

on other metabolites also failed to produce toxicity (27,43)
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indicating that the toxicity of chloramphenicol in newborns
was probably due to the free antibiotic.
In infants the amount of free chloramphenicol excreted
in the urine is similarly 5-10% but the excretion of the
glucuronide is considerably less than normal (50% of the
dose).

There is also a higher proportion of the glucuronide

in the blood of newborns in addition to high, prolonged levels
of free chloramphenicol.

This appears to be the result of

both poor renal function and a deficient glucuronide conjugating system.
Analogous studies to those in the newborn were performed on adult patients with hepatic cirrhosis which revealed that the half-life for active chloramphenicol was
markedly prolonged.

However, the defect was in the rate of

conversion to the glucuronide not the total amount converted.
In patients with acute renal failure the half-life for active
chloramphenicol was not prolonged but high levels of the chloramphenicol glucuronide were found in the blood.
occurred.

No toxicity

This prolonged serum half-life and accumulation of

metabolic products in these anuric patients indicates that
removal other than by renal mechanisms is slow (less than 1%
per hour).(43)

The glucuronide conjugate is excreted by renal

tubular secretion while the free drug is excreted by glomerular filtration.(36)
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Experimental work with creatinine excretion suggests
that the tubules of newborn infants have not yet developed
the ability to excrete this substance.(45)

Driscoll reported

infant glomerular filtration rates for inulin, mannitol and
creatinine to be 30 to 50 per cent of adult levels.

The clear-

ances of para-aminohippurate and iodopyrcet were 20 to 40 per
cent those in the adult.(46)

DISCUSSION
Following the numerous reports of the

Il

gray syndrome lf

in 1951 to 1959. the physiologic explanation of chloramphenicol~toxicity

was based on the excessive doses used between

1951 and 1959 together with reduced glucuronide conjugation
and impaired renal excretion.

This resulted in toxic blood

levels above 100 micrograms per milliliter.

This potential

toxicity was an important consideration until the infant became approximately three weeks of age.

The conclusions of

these authors were that the free drug was the toxic component,
and although the mechanism of action was unknown, the toxic
reactions were related to the impaired glucuronide conjugation
and impaired renal excretion.
These conclusions do not satisfy the question why the
excessive concentration of the chloramphenicol molecule results in the clinical picture of cardiovascular collapse.
Further research in the literature revealed that Japanese
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writers in 1952 studied the effects of various antibiotics on
blood pressure and respiration in the rabbit.(47)
phenicol was the most potent drug.

Chloram-

Large doses produced

slight to moderate decreases in blood pressure, bradycardia,
and decreased amplitude of respiration which did not parallel
the dosages used.

The blood pressure drop was believed to be

peripheral in origin and chiefly responsible for the cardiac
action.

They also noted that chloramphenicol in concentration

of 1:5000 to 1:4000 stimulated a segment of frog intestine
but in concentrations of 1:10,000 produced inhibition only.
Swain (48) also found chloramphenicol the most potent
cardiac depressant as compared with other antibiotics.

Using

a dog heart-lung preparation he induced heart failure with a
100 t.o 200 mg dose of chloramphenicol.

The failure was slowly

reversed by ouabain and promptly reversed by 100 mg of calcium
chloride.

Successive episodes of heart failure required

smaller and smaller doses of chloramphenicol and progressively
larger doses of calcium chloride to reverse it.

The drug's

cardiac depressant actions were found to be indistinguishable
from pentobarbital, and on a molar basis chloramphenicol was
more potent.
A technique for titrating calcium ions was developed to
determine if the agents bound the ion.

By this method Swain

concluded that chloramphenicol acted by removing ionized cal-
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cium from the environment of the heart rather than binding
the ca1cium ion, because ca1cium ch10ride wou1d not comp1ete1y
reverse severa1 consecutive episodes of heart fai1ure.

A1-

though the experiment is significant, his conc1usions do not
consider that there may be other mechanisms for the cardiac
.fai1ure.
Kretchmer specu1ated that the toxicity in infants cou1d
be exp1ained by the action of ch10ramphenic01 on protein synthesis. (49)

Ch10ramphenic01 is a se1ective inhibitor of pro-

tein synthesis.

The RNA formed in the presence of ch10ram-

phenic01 is abnorma1 being unstab1e fo110wing the drugs remova1.

The hypothesis is that ch10ramphenic01 b10cks the

conversion of the'unstab1e RNA polymer to a stab1e ribonucleoprotein. (50)
Roblin (51) has shown that the antibacterial action of
smal1 concentrations of chloramphenicol toward Escherchia
coli is reversed by phenylalanine which has a simi1ar
ture.

This appears to be a non-competitive inhibition between

the chloramphenicol and phenyla1anine molecules •

.;-====\ . NHCOCHC12
N0 2

struc~

~CHORCHCH20H

phenylalanine

chloramphenicol
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Although antibiotics are not generally believed to
function as metabolic antagonists, it could be speculated
that the chloramphenicol molecule might have an inhibitory
effect on the synthesis of catecholamines since tyrosine, the
initial step in the pathway to epinephrine, is formed from
phenylalanine.

The structures of chloramphenicol and epi-

nephrine are also similar.

NHCOCHCl
,
N02"

~HCH3

2

CHOHCHCH2 0H

HO

~

CHOHCH2

HOi""--..........,
epinephrine

chloramphenicol

This possibility seems more likely as a cause for cardiovascular collapse when it is recalled that the opposite
effects of catecholamines were obtained with the heart-lung
preparation, frog intestine and rabbit experiments.

Disturbed

carbohydrate metabolism with fasting hypoglycemia was noted
as well as the clinical course of the infants affected.

SUMMARY
Chloramphenicol toxicity in the newborn, Le. the

U gray

syndrome tf is described and the findings of the various workers
are presented.

Two case reports describe the typical onset

of symptoms and the insidious way in which this toxicity manifests itself.
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As a result of the increased mortality rates in newborn
nurseries several series of these deaths were collected and
animal studies were obtained to compare the tolerance of newborn animals to adult animals.
Blood level studies by Parke, Davis and Company are
presented and the different forms of the antibiotic are considered.

Additional unpublished data on chloramphenicol suc-

cinate is also presented.
Emphasis is placed on the metabolic disposition of chloramphenicol because of the development of hepatic and renal
function in the infant.
Because the data obtained did not adequately explain why
cardiovascular collapse occurred in these infants, a discussion of the effects of chloramphenicol an the cardiovascular
system and speculation of the possible mechanisms involved are
presented.
CONCLUSIONS
Chloramphenicol is toxic to premature infants and newborns up to three weeks of age when blood levels exceed 100
micrograms per milliliter.

This toxicity is manifested by

circulatory collapse and termed the "gray syndrome fl •

Effec-

tive blood levels of 10 micrograms per milliliter are usually
obtained with doses of 25 mg per kilogram per day for premature
and newborn infants.

Full term infants may receive from 25 to
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50 mg per kilogram per day, but the data suggests that full
term infants probably do not handle the drug any more effectively than the prematures.

Most of the deaths occurred fol-

lowing doses of 100 to 150 mg per kilogram per day, although
the experiments show that toxic levels may be reached with
50 mg per kilogram.
The mechanism of this toxicity is unknown but the evidence in the literature indicates that it is related to reduced detoxication by the glucuronide conjugation pathway and
poor renal excretion resulting in abnormally high blood levels
/

of the free antibiotic.
An attempt to explain why this toxicity is manifested
by cardiovascular collapse resulted in speculation by several
authors.

Chloramphenicol produced a decrease in blood pressure

and respiration in rabbits which was thought to be peripheral
in origin.

It produced cardiac failure in a dog heart-lung

preparation which was thought to occur as a result of a decrease in calcium ion available to the myocardium.
There is some evidence that chloramphenicol and phenylalanine are antagonistic in biological systems.

Speculation

along these lines includes the possiQility that chloramphenicol
may exert some antagonism to the synthesis of catecholamines
in the pathway from phenylalanine to epinephrine.

This hy-

pothesis could perhaps be supported with animal experiments
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which include the determination of urinary catecholamines
during chloramphenicol administration.

There is no indication

in the literature that this has been done.(52)

Further work

utilizing data from Swain's experiments may aid in identifying
the cause of the "gray syndrome".
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